<DOC>
	<DOCNO>NCT00466986</DOCNO>
	<brief_summary>The purpose study determine combination Abraxane Carboplatin together improve chance control recurrent ovarian/fallopian tube/peritoneal cancer .</brief_summary>
	<brief_title>Abraxane Plus Carboplatin Recurrent Platinum-Sensitive Ovarian Cancer</brief_title>
	<detailed_description>Current best practice recommend Carboplatin combined Taxol treatment Ovarian cancer . Taxol paclitaxel solvent Cremophor-El solvent associate significant side effect e.g . anaphylaxis hypersensitivity . require routine use premedication antihistamine steroid . Abraxane contrast Cremophor-El free protein bound . This 2 advantage Taxol . 1 . No need routine premedications 2 . Increased drug entry cell facilitate great potential anti-tumor activity . Schedule : Carboplatin day1 every 28days . Abraxane day1,8,15 every 28days .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Histologically cytologically confirm recurrent epithelial ovarian primary peritoneal carcinoma . Patient stag diagnosis accord FIGO Classification . 2 . Measurable Disease RECIST Criteria ( define presence least 1 measurable lesion ( see Section 7.7.1 definition measurable lesion ) elevate CA125 absence measurable disease . A pretreatment sample CA125 collect within 2 week treatment start . A pretreatment sample CA125 least twice upper limit normal . 3 . Patients must disease recurrence 6 month completion frontline platinum paclitaxelcontaining regimen . Duration response prior therapy prior consolidation therapy document case report form descriptive analysis . 4 . Patients must receive least 3 cycle frontline taxane platinumcontaining regimen prior entry study . 5 . Patients must document complete clinical response frontline therapy . 6 . Patients must diseasefree prior malignancy 5 year exception curativelytreated basal cell squamous cell carcinoma skin carcinoma situ cervix . 7 . Life expectancy &gt; 6 month . 8 . ECOG ( Zubrod ) performance status 02 . 9 . Age &gt; 18 year . 10 . Patient follow blood count Baseline : ANC &gt; 1.5 x 109 c/L ; platelet &gt; 100 x 109 c/L ; Hgb &gt; 9 g/dL . 11 . Patient follow blood chemistry level Baseline : AST ( SGOT ) , ALT ( SGPT ) &lt; 1.5x upper limit normal range ( ULN ) ; total bilirubin NORMAL ; alkaline phosphatase &lt; 2.5x ULN creatinine &lt; 1.5 mg/dL . 12 . Patient his/her legally authorize representative guardian inform nature study , agree participate study , sign Informed Consent form prior participation studyrelated activity . 1 . Patients receive one prior chemotherapy regimen . 2 . Evidence active brain metastasis , include leptomeningeal involvement . Prior evidence brain metastasis permit treated stable therapy least 1 month . 3 . Patient preexist peripheral neuropathy grade &gt; /= 2 ( per National Cancer Institute [ NCI ] Common Terminology Criteria Adverse Events version 3.0 [ CTCAE ] . 4 . Patients receive concurrent intervene chemotherapy , hormonal ( treatment ovarian carcinoma ) , immunotherapy , radiotherapy . 5 . Patient clinically significant concurrent illness . 6 . Patient , Investigator 's opinion , unlikely able complete study End Study ( EOS ) visit . 7 . Patient history allergy hypersensitivity study drug . 8 . Patient serious medical risk factor involve major organ system investigator considers unsafe patient receive experimental research drug . 9 . Patient enrol clinical protocol investigational trial . 10 . Patients childbearing potential , practice adequate contraception .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>recurrent</keyword>
	<keyword>ovarian</keyword>
	<keyword>cancer</keyword>
	<keyword>platinum sensitive</keyword>
</DOC>